DANIEL VERINA: Open Payments
NPI 1083929897 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$73,535 in 155 payments from 12 companies in 2025. Trend: 2023 $84,740 · 2024 $115,593 · 2025 $73,535
Speaker / faculty: $55,874Travel & lodging: $11,372Food & beverage: $4,897Grant: $1,000Honoraria: $230Education: $100
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 91 | $65,667 |
| GENZYME CORPORATION | 12 | $3,108 |
| GlaxoSmithKline, LLC. | 9 | $1,556 |
| PFIZER INC. | 7 | $1,529 |
| Karyopharm Therapeutics Inc. | 17 | $590 |
| Legend Biotech USA Inc. | 5 | $329 |
| Adaptive Biotechnologies Corporation | 6 | $249 |
| Kite Pharma, Inc. | 2 | $230 |
| Janssen Scientific Affairs, LLC | 1 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $89 |
Products named: RYBREVANT, SARCLISA, ELREXFIO, XPOVIO, TECVAYLI, DARZALEX, CARVYKTI, clonoSEQ.
Industry payments across NY — which companies pay providers there.
